Rituximab versus intravenous cyclophosphamide in sufferers with connective tissue disease-associated interstitial lung illness within the UK (RECITAL): a double-blind, double-dummy, randomised, managed, part 2b trial


Interstitial lung illness (ILD) is a frequent, usually deadly, complication of systemic autoimmune ailments together with systemic sclerosis, idiopathic inflammatory myositis, and combined connective tissue illness (CTD).

Based mostly on trials in sufferers with systemic sclerosis-associated ILD, immunosuppressive remedy with cyclophosphamide is incessantly used as an efficient therapy for people with extreme or quickly progressive CTD-associated ILD (CTD-ILD); nevertheless, cyclophosphamide use is proscribed by toxicity. Cyclophosphamide incessantly causes nausea, gastrointestinal upset, and haematuria, could cause gonad-failure in each women and men, and will increase threat of bladder malignancy. This latter impact is dose associated and due to this fact limits particular person cumulative lifetime use of cyclophosphamide to lower than 20 g.

  • Tashkin DP
  • Elashoff R
  • Clements PJ
  • et al.
Cyclophosphamide versus placebo in scleroderma lung illness.